Citadel Advisors’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Citadel Advisors’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,711	Closed	-$31.3K	–	15884
2023 Q4	$31.3K	Sell	1,711 -82	-5%	-$1.28K	﹤0.01%	12232
2023 Q3	$44.8K	Buy	+1,793	New	+$60.2K	﹤0.01%	11874
2022 Q3	–	Hold	0	–	-$7K	–	14299
2022 Q2	–	Hold	0	–	–	–	12659
2021 Q4	–	Sell	-1	Closed	-$43K	–	15333
2021 Q3	$43K	Buy	+1	New	+$58.5K	﹤0.01%	13450

Citadel Advisors's PBLA Position: Q1 2024 in Review

Citadel Advisors sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2024, closing a stake of 1,711 shares — an estimated $31.3K sold.

Citadel Advisors first reported a position in PBLA in Q3 2021 and held it in 3 quarters. The position peaked at $44.8K in Q3 2023. 0 funds tracked by Wall St. Rank hold PBLA as of Q1 2024.

Citadel Advisors reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 1,711 Panbela Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $31.3K.
Citadel Advisors first reported a position in Panbela Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
Citadel Advisors's Panbela Therapeutics, Inc. Common Stock position peaked at $44.8K in Q3 2023.
0 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.